A Dose Blocked-randomized, Double-blind, Placebo Controlled, Single and Multiple Dosing, Dose-escalation Phase I Clinical Trial to Investigate the Safety, Tolerability, Pharmacokinetic/Pharmacodynamics and Food Effect of LC51-0255

Trial Profile

A Dose Blocked-randomized, Double-blind, Placebo Controlled, Single and Multiple Dosing, Dose-escalation Phase I Clinical Trial to Investigate the Safety, Tolerability, Pharmacokinetic/Pharmacodynamics and Food Effect of LC51-0255

Active, no longer recruiting
Phase of Trial: Phase I

Latest Information Update: 21 Jul 2017

At a glance

  • Drugs LC51 0255 (Primary)
  • Indications Inflammation
  • Focus Adverse reactions
  • Sponsors LG Chem
  • Most Recent Events

    • 16 Jul 2017 Planned End Date changed from 31 Oct 2018 to 30 Nov 2018.
    • 16 Jul 2017 Planned primary completion date changed from 31 Aug 2018 to 31 Jul 2018.
    • 16 Jul 2017 Status changed from recruiting to active, no longer recruiting.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top